INOVIQ Ltd (ASX:IIQ) has reported a net loss of $7.5 million for the financial year ended 30 June 2026, with the company disclosing that an expanded clinical study for its EXO-OC™ ovarian cancer test ended in failure due to poor quality samples sourced from commercial biobanks.

Key Points

  • INOVIQ reported a net loss of $7.5 million for the financial year ended 30 June 2026.
  • An expanded retrospective study using 1,200 samples from five different biobanks was rendered unusable due to sample quality issues.
  • The company raised $10.2 million during FY2026 to support its strategic priorities.
  • INOVIQ appointed Peter Gunzburg as Chairman and Dr Rebecca Lim as Chief Scientific Officer during the year.
  • The company expects to report findings from its independent review of the study to the market in September 2026.

EXO-OC™ Expanded Clinical Study Failure

INOVIQ's expanded retrospective clinical study using 1,200 commercially biobanked samples from five different biobanks was conducted in accordance with internationally accepted guidelines, including samples remaining blinded until final analysis. The company disclosed that all samples were found to be unfit for purpose, rendering the study results unusable. The company stated it is conducting a comprehensive review of the study, supported by independent external expertise, with the objectives of fully understanding the key issues and refining the path forward. The review is described as well advanced but incomplete, with a full explanation committed for September 2026.

EXO-OC™ Commercialisation Pathway and CAR-Exosome Program

INOVIQ disclosed it is advancing EXO-OC™ toward initial commercialisation as a Laboratory Developed Test (LDT) in the United States through a CLIA-certified laboratory. The company's longer-term intention is to progress toward an In Vitro Diagnostic (IVD) to expand market reach and support reimbursement. In parallel, the company's CAR-exosome therapeutics program has demonstrated proof-of-concept data across multiple cancer models, including breast, lung and ovarian cancer models, and is being advanced toward manufacturing readiness and first-in-human studies, according to the filing.

Capital Raising, Leadership Changes and EXO-NET® Partnership

During FY2026, INOVIQ raised $10.2 million to support its strategic priorities. The company expanded its leadership team with the appointment of Peter Gunzburg as Chairman and Dr Rebecca Lim as Chief Scientific Officer. The filing also noted continued growth in the global reach of the company's EXO-NET® business through its partnership with Promega. INOVIQ's proprietary technologies generate early revenue through commercial research tools, which the company disclosed underpin a growing pipeline of diagnostics and therapeutics products.